Daratumumab Interference in Pretransfusion Testing Is Overcome by Addition of Daratumumab Fab Fragments to Patients’ Plasma

Interference of daratumumab with pretransfusion testing, mimicking a high-titer, low avidity like antibody

Daratumumab is a monoclonal immunoglobulin against CD38 and has been approved for treating patients with refractory multiple myeloma. The presence of daratumumab in the sera can interfere with pretransfusion testing due to the weakly expression of CD38 on red cells. The reactivity could be mistaken as autoantibody (if autocontrol is positive) or alloantibody (if autocontrol is negative). We pre...

Infection Risk Associated with Daratumumab

Potential role of daratumumab in the treatment of multiple myeloma

Multiple myeloma is the second most common hematologic malignancy in the US. Treatments utilizing alkylating agents, corticosteroids, proteasome inhibitors, and immunomodulatory drugs have resulted in significant survival benefits, however, despite the advances, relapse is inevitable. Decreased depth and duration of response obtained with each successive relapse of disease is typical of the dis...

Role of daratumumab in transfusion medicine: a must know entity

Drug interference in serological assays is a well-known phenomenon. Therapeutic monoclonal antibodies (MoAbs) have been successful in treating a variety of malignancies. Some of these MoAbs interfere in day-to-day laboratory tests. Recently, a novel targeted immunotherapy, daratumumab (MoAb against CD38 antigen) was approved for treating advanced stage multiple myeloma (MM).1 Herein, we describ...

evaluation of fat atrophy in patients with dermis fat graft of orbit by ct-scan

چکیده ندارد.